Rxivist logo

Tumor PD-L1 selectively suppresses type I interferon in myeloid cells to suppress CTL recruitment to promote lung metastasis

By John D Klement, Priscilla S Redd, Chunwan Lu, Alyssa D Merting, Dakota B Poschel, Dafeng Yang, Gang Zhou, David H Munn, Kebin Liu

Posted 18 Jun 2021
bioRxiv DOI: 10.1101/2021.06.18.449028

The mechanism underlying tumor cell PD-L1 (tPD-L1) induction of immune suppression through T cell PD-1 is well-known, but the mechanism underlying tPD-L1 induction of immune suppression via an intermediate cell is incompletely understood. We report here that tPD-L1 does not suppress cytotoxic T lymphocyte (CTL) activation and lytic function when only tumor cells and CTLs are present. Strikingly, knocking out PD-L1 in tumor cells has no effect on primary tumor growth, but significantly decreases lung metastasis in a CTL-dependent manner. Depletion of myeloid cells impaired tPD-L1 promotion of lung metastasis. Single-cell RNA sequencing revealed that tPD-L1 engages myeloid PD-1 (mPD-1) to antagonize type I interferon (IFN-I) and STAT1 signaling to repress Cxcl9 and Cxcl10 expression to impair CTL recruitment to lung metastases. Human patient response to PD-1 blockade immunotherapy correlates with IFN-I response in myeloid cells. Our data determines that the tPD-L1/mPD-1/IFN-I/STAT1/Cxcl9/10 axis controls CTL tumor infiltration in lung metastasis.

Download data

  • Downloaded 246 times
  • Download rankings, all-time:
    • Site-wide: 135,375
    • In cancer biology: 4,136
  • Year to date:
    • Site-wide: 83,631
  • Since beginning of last month:
    • Site-wide: 77,570

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide